Adjuvant imatinib for GIST: duration likely matters
Mikael Eriksson, Heikki Joensuu
Topics & Concepts
MedicineGiSTImatinibImatinib mesylatePDGFRAInternal medicineStromal tumorTyrosine-kinase inhibitorOncologySunitinibTyrosine kinaseSarcomaStromal cellCancerGastroenterologyPathologyMyeloid leukemiaReceptorGastrointestinal Tumor Research and TreatmentGastric Cancer Management and OutcomesGastrointestinal disorders and treatments